Operating cash flow increased 68.4%
Operating cash flow changed +68.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating cash flow changed +68.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Shares outstanding changed +156.8% from the comparable as-filed period. The change ranks at the 75th percentile of 8 prior comparable changes. This reverses 3 consecutive comparable moves in the opposite direction.
Operating income changed -199.6% from the comparable as-filed period.
Operating margin changed -609 basis points from the comparable as-filed period.
Gross margin changed +2248 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Net income changed -222.7% from the comparable as-filed period.
Revenue changed +158.4% from the comparable as-filed period.
Current liabilities changed +406.2% from the comparable as-filed period.
Total assets changed +405.5% from the comparable as-filed period.
Trade receivables changed +232.2% from the comparable as-filed period.
Operating cash-flow margin changed +6500 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Receivables / revenue changed +1496 basis points from the comparable as-filed period.
Current ratio changed -78.5% from the comparable as-filed period.
Working capital / assets changed -4778 basis points from the comparable as-filed period.
Short-term borrowings changed +2108.4% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Current assets changed +8.8% from the comparable as-filed period.
Working capital changed -211.2% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Research & development changed -7.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Gross profit changed +0.0% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a zero base.
R&D / revenue changed -99 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.